Clinical Trials Browser

Endometrial Neoplasms × camrelizumab × Clear all

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Phase 2 Recruiting

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

NCT05550558 2022-09-28

CAN-RESPOND

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Phase 2 Unknown

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms